Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

被引：3
|
作者：
Andre, T. [1 ,2 ]
Berton, D. [3 ,4 ]
Oaknin, A. [5 ]
Moreno Garcia, V. [6 ]
Curigliano, G. [7 ,8 ]
Trigo, J. [9 ]
Barretina-Ginesta, M-P. [10 ]
Ellard, S. [11 ]
Tinker, A. V. [12 ]
Miller, R. [13 ]
Pikiel, J. [14 ]
Boni, V. [15 ]
Cresta, S. [16 ]
Pothuri, B. [17 ]
Perez, D. Roda [18 ]
Drew, Y. [19 ]
Veneris, J. [20 ]
Im, E. [21 ]
Banerjee, S. [22 ]
机构：
[1] Sorbonne Univ, Med Oncol, Paris, France
[2] St Antoine Hosp, Paris, France
[3] GINECO, Med Oncol Dept, St Herblain, France
[4] Ctr Rene Gauducheau, Inst Cancerol lOuest, St Herblain, France
[5] Vall Hebron Inst Oncol VHIO, Vall DHebron Univ Hosp, Med Oncol, Barcelona, Spain
[6] Fdn Jimenez Diaz Hosp, START Madrid FJD, Clin Res, Madrid, Spain
[7] European Inst Oncol IRCCS, Div Early Drug Dev, IEO, Milan, Italy
[8] Univ Milan, Milan, Italy
[9] Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain
[10] Inst Catala Oncol, Med Oncol Serv, Girona, Spain
[11] BC Canc Kelowna, Med Oncol, Vancouver, BC, Canada
[12] BC Canc, Med Oncol, Vancouver, BC, Canada
[13] UCL, St Bartholomews Hosp London, Med Oncol, London, England
[14] Reg Ctr Oncol, Med Oncol, Gdansk, Poland
[15] Hosp Univ HM Sanchinarro, START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Early Drug Dev Unit, Madrid, Spain
[16] IRCCS Ist Nazl Tumori Fdn, Med Oncol, Milan, Italy
[17] NYU Langone Hlth, Laura & Isaac Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, Obstet & Gynecol, New York, NY USA
[18] Univ Hosp, Dept Med Oncol, Valencia, Spain
[19] Newcastle Hosp NHS Fdn Trust, Northern Ctr Canc Care, Med Oncol, Newcastle Upon Tyne, Tyne & Wear, England
[20] GlaxoSmithKline, Oncol Clin Dept, Waltham, MA USA
[21] GlaxoSmithKline, Clin Dev, Waltham, MA USA
[22] Royal Marsden Hosp NHS Fdn Trust, Gynaecol Dept, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1375
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
991P
引用
收藏
页码：S845 / S846
页数：2
相关论文
共 50 条
  • [41] Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
    Ouyang, Tao
    Cao, Yanyan
    Kan, Xuefeng
    Chen, Lei
    Ren, Yanqiao
    Sun, Tao
    Yan, Liangliang
    Xiong, Bin
    Liang, Bin
    Zheng, Chuansheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] CLINICAL OUTCOMES AND TREATMENT-RELATED ADVERSE EVENTS TO TOCILIZUMAB IN SARS-COV-2 ILLNESS
    Ahmad, S.
    Jenkinson, E.
    Carney, R.
    Nahu, T.
    Quinn, J.
    Dwarakanath, A.
    THORAX, 2021, 76 : A169 - A169
  • [43] Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
    Daud, Adil
    Tsai, Katy
    ONCOLOGIST, 2017, 22 (07): : 823 - 833
  • [44] The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review
    Coca-Pelaz, Andres
    Halmos, Gyorgy B.
    Strojan, Primoz
    de Bree, Remco
    Bossi, Paolo
    Bradford, Carol R.
    Rinaldo, Alessandra
    Vander Poorten, Vincent
    Sanabria, Alvaro
    Takes, Robert P.
    Ferlito, Alfio
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (07): : 2410 - 2429
  • [45] Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis
    Karna, Rahul
    S Deliwala, Smit
    Ramgopal, Balasubramanian
    Asawa, Palash
    Mishra, Rahul
    P Mohan, Babu
    Jayakrishnan, Thejus
    Grover, Dheera
    Kalra, Tanisha
    Bhalla, Jaideep
    Saraswati, Ushasi
    Gangwani, Manesh K.
    Dhawan, Manish
    Adler, Douglas G.
    IMMUNOTHERAPY, 2023, 15 (10) : 773 - 786
  • [46] Impact of obesity on treatment-related adverse events, disease recurrence, and survival in women with cervical carcinoma
    Gross, Jeffrey P.
    Strauss, Jonathan B.
    Lurain, John
    Berry, Emily
    Neubauer, Nikki
    Helenowski, Irene
    Donnelly, Eric D.
    JOURNAL OF RADIATION ONCOLOGY, 2016, 5 (02) : 197 - 203
  • [47] Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
    Briggs, Andrew
    Wild, Diane
    Lees, Michael
    Reaney, Matthew
    Dursun, Serdar
    Parry, David
    Mukherjee, Jayanti
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2008, 6 (1)
  • [48] Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
    Andrew Briggs
    Diane Wild
    Michael Lees
    Matthew Reaney
    Serdar Dursun
    David Parry
    Jayanti Mukherjee
    Health and Quality of Life Outcomes, 6
  • [49] MANAGEMENT OF TREATMENT-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH MOGAMULIZUMAB: A SINGLE-CENTER EXPERIENCE
    Turba, Elyce
    Whiddon, Shannen
    Salamanca, Christopher
    Cisneros, Jennifer
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [50] Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials
    Venkatachalam, Meena
    Stenehjem, David D.
    Pietri, Guilhem
    Penrod, John R.
    Korytowsky, Beata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345